The effect of intravenous immunoglobulin on pregnancy outcomes of recurrent spontaneous abortion combined with antiphospholipid syndrome:a multi-center clinical trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037511

Enrollment

Unknown

Registered

2020-08-28

Start date

2020-12-01

Completion date

Unknown

Last updated

2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent spontaneous abortion

Interventions

control group:aspirin+low molecular weight heparin+prednisone

Experimental group:aspirin+low molecular weight heparin+prednisone+intravenous immunoglobulin

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Aged 20 to 35 years; 2. Diagnosed as recurrent spontaneous abortion combined with antiphospholipid syndrome; 3. Clinically need the IVIG therapy; 4. Get the proper informed consent.

Exclusion criteria

Exclusion criteria: 1. Etiologically classified as chromosome abnormality; 2. Diagnosed as primary infertility; 3. Combined with other high-risk factors of RSA; 4. Tested positive for HIV or hepatitis virus or liver function abnormality; 5. Allergic to any medicine in the trial; 6. Does not plan to conceive; 7. Refuse to join the trial.

Design outcomes

Primary

Measure	Time frame
Pregnancy success rate;	—

Secondary

Measure	Time frame
pregnancy complications;placenta blood flow;maternal immunity;	—

Countries

China

Contacts

Public ContactLiping Jin

Shanghai First Maternity and Infant Hospital

jinlp01@163.com+86 18918779150

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026